<DOC>
	<DOC>NCT00267683</DOC>
	<brief_summary>This trial is conducted in Japan. This is a clinical trial to study the efficacy and safety of thrice daily Insulin Aspart compared to Glibenclamide in type 2 diabetic patients.</brief_summary>
	<brief_title>Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s) other than SU agents for at least 12 weeks No previous treatment with insulin and/or SU agents HbA1c between 7.5% and 10.0% Body Mass Index (BMI) below 30.0 kg/m2 Proliferative retinopathy or maculopathy requiring acute treatment Impaired hepatic function Impaired renal function Cardiac diseases Uncontrolled hypertension Known hypoglycaemia unawareness or recurrent major hypoglycaemia Current treatment with systemic corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>